SOURCE: Entest BioMedical Inc.

July 26, 2011 08:00 ET

Entest BioMedical Unit Prepares to Enter the $58 Billion U.S. Pet Products Market by Establishing Online Veterinary Products Store

Market Research Estimates the U.S. Pet Products Industry to Exceed $58 Billion in Sales for 2011, Climbing to $74 Billion in Sales by 2015

SAN DIEGO, CA--(Marketwire - Jul 26, 2011) - Entest BioMedical, Inc. (OTCQB: ENTB) (OTCBB: ENTB) today announced plans to establish a website through which the Company intends to retail pet food, toys and other pet related items at competitive prices nationwide. The online store is scheduled to be launched in August of 2011.

A spokesperson for Entest BioMedical, Inc. noted that Packaged Facts, a leading market research firm, states that U.S. pet industry related sales will hit $58 billion in 2011 and climb to more than $74 billion in 2015. Entest is confident that significant revenue can be realized by the Company through online sales of pet products.

Entest's Chairman & CEO David Koos stated, "Our initial plan was for McDonald Animal Hospital (our wholly owned veterinary hospital) to set up online pet product sales as a convenience for its patient base. However, after evaluating the potential, Entest management decided to offer online pet product sales to the general public in an attempt to capture a portion of the billions generated annually through sales of pet products."

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCQB: ENTB) (OTCBB: ENTB) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The company's products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). The company's immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure.


This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information

  • Contact:

    Entest BioMedical Inc.
    David R. Koos
    Chairman & CEO
    619.702.1404 Direct
    619.330.2328 Fax
    Email Contact

    For further information:

    A. S. Austin Company
    3755 Avocado Blvd., #516
    La Mesa, CA 91941